BioNTech (BNTX) Projected to Post Quarterly Earnings on Wednesday

BioNTech (NASDAQ:BNTX) is projected to announce its earnings results before the market opens on Wednesday, March 19th. Analysts expect the company to announce earnings of $0.38 per share for the quarter. BioNTech has set its FY 2025 guidance at EPS.Investors interested in participating in the company’s conference call can do so using this link.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.24 billion. During the same quarter in the prior year, the company posted $1.90 earnings per share. The firm’s revenue was down 19.5% on a year-over-year basis. On average, analysts expect BioNTech to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

BioNTech Trading Up 1.4 %

NASDAQ:BNTX opened at $100.86 on Tuesday. The stock’s 50 day moving average price is $115.11 and its 200 day moving average price is $113.46. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a market capitalization of $24.18 billion, a P/E ratio of -48.03 and a beta of 0.30. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33.

Wall Street Analyst Weigh In

Several brokerages have commented on BNTX. Wells Fargo & Company began coverage on BioNTech in a report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 price target on the stock. JPMorgan Chase & Co. lowered their price target on BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a report on Tuesday, November 26th. Evercore ISI upgraded BioNTech from an “in-line” rating to an “outperform” rating and increased their price target for the company from $110.00 to $125.00 in a report on Tuesday, November 19th. Canaccord Genuity Group reiterated a “buy” rating and set a $171.44 price target on shares of BioNTech in a report on Tuesday, March 11th. Finally, BMO Capital Markets increased their price target on BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a report on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $143.73.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.